Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success
By optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.
Authors
- Jonathan Krell (ORCID: https://orcid.org/0000-0002-9835-9227)
- Laura A. Tookman (ORCID: https://orcid.org/0000-0003-0752-3974)
- Sadaf Ghaem‐Maghami (ORCID: https://orcid.org/0000-0002-7369-5080)
- Will Loughborough (ORCID: https://orcid.org/0000-0002-9208-5122)
- Ankit Chadha (ORCID: https://orcid.org/0000-0002-5089-3877)
- Georgina Keogh (ORCID: https://orcid.org/0009-0004-3706-5980)
- Jacqueline McDermott (ORCID: https://orcid.org/0000-0001-8052-7133)
- Jack Thompson (ORCID: https://orcid.org/0000-0001-9526-5447)
- Iain A. McNeish (ORCID: https://orcid.org/0000-0002-9387-7586)
- Ashton Hunt (ORCID: https://orcid.org/0009-0003-4166-1358)
- Daria Ditri
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Royal United Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1080/14796694.2024.2433412
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- AstraZeneca
- International Society of Ultrasound in Obstetrics and Gynecology